---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-000231"
form_type: "8-K"
ticker: null
cik: "0001300734"
company_name: "SHINECO, INC."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:12:02.468820+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shineco completes acquisition of 51% of Changzhou Biowin Pharmaceutical for $9M cash + 3.26M shares

## Summary
- Total consideration ~$12.1M: $9M cash plus 3.26M SISI shares valued at $0.95/share (~$3.1M).
- Acquisition closed Dec 30, 2022; subsidiary Shineco Life Science Research acquired 51% stake from Beijing Kanghuayuan.
- Performance targets for 2023-2025: 2023 rev >=RMB35M, net profit >=RMB5.5M; 2024 rev >=RMB50M, net profit >=RMB10M; 2025 rev >=RMB80M, net profit >=RMB20M.
- Financial statements of Biowin to be filed by amendment within 71 days of 8-K.

## SEC filing metadata
- accession: 0001493152-23-000231
- form_type: 8-K
- cik: 0001300734
- company_name: SHINECO, INC.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1300734/000149315223000231/0001493152-23-000231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1300734/000149315223000231/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-000231
- JSON: https://secwatch.observer/filing/0001493152-23-000231.json
- Plain text: https://secwatch.observer/filing/0001493152-23-000231.txt

## Key facts
- M&A Transactions
  SHINECO, INC. completed an acquisition involving Beijing Kanghuayuan Medicine Information Consulting Co., Ltd. for US $9 million in cash and the Company issued 3,260,000 shares of the Company’s common stock (closed 2022-12-30).
  - Action: acquisition
  - Counterparty: Beijing Kanghuayuan Medicine Information Consulting Co., Ltd.
  - Consideration: US $9 million in cash and the Company issued 3,260,000 shares of the Company’s common stock
  - Closing: 2022-12-30
  source text: established under the laws of China (“Seller”) Biowin, the Company and Subsidiary (the “Agreement”). As the consideration for the acquisition, the Company paid to Seller US $9 million in cash and the Company issued 3,260,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) to the equity holders of Biowen or
  evidence_url: https://www.sec.gov/Archives/edgar/data/1300734/000149315223000231/0001493152-23-000231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.